Latest News and Press Releases

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with...

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...

NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...

BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...

BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...

BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...

BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...